Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study

Table 2 Follow-up data for all patients in the study

		Treated with corticosteroid therapy?
	Total (n = 143)	Yes (n = 40)	No (n = 103)	p-value
Time from diagnosis until ESKD (years)	5 (2–9)	5 (2–10)	5 (2–9)	0.98
RAS blockade (yes)	132 (94)^a	38 (95)	94 (94)^a	1.0
UACR (mg/mmol) before RAS blockade	300 (180–520)	508 (248–717)	265 (173–408)	0.0015
UACR (mg/mmol) after RAS blockade	140 (86–250)	210 (133–536)	120 (73–202)	< 0.001
Proteinuria (g/24 h) before RAS blockade	3.0 (1.8–5.2)	5.1 (2.5–7.2)	2.7 (1.7–4.1)	0.0015
Proteinuria (g/24 h) after RAS blockade	1.4 (0.9–2.5)	2.1 (1.3–5.4)	1.2 (0.7–2.0)	< 0.001
Reduction in proteinuria (g/24 h) during RAS blockade	1.5 (0.7–2.2)	1.7 (0.9–2.8)	1.4 (0.7–2.1)	0.27

For quantitative variables, values are expressed as medians (interquartile ranges), and for qualitative variables, values are expressed as n (%). The p-value was based on Fisher’s exact test for categorical variables and the Mann–Whitney U test for continuous variables. The p-value is here only meant to be a descriptive measure, since we have not adjusted for possible confounders
ESKD end-stage kidney disease, RAS renin-angiotensin system, UACR Urine albumin-to-creatinine ratio
^aThree patients had missing data. Therefore, they were excluded from further analyses

ISSN: 1471-2369